Omeros (LTS:0KBU) Future 3-5Y EPS without NRI Growth Rate : 16.38 (As of Dec. 13, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Omeros Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Omeros's Future 3-5Y EPS without NRI Growth Rate is 16.38.

Competitive Comparison of Omeros's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Omeros's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Omeros's Future 3-5Y EPS without NRI Growth Rate falls into.

Omeros (LTS:0KBU) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Omeros Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Omeros's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (LTS:0KBU) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Headlines

No Headlines